Skip to main content

Table 4 Cox multivariate analysis of the survival in recurrent breast cancer by breast cancer subgroup

From: Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000

  HR-positive/HER-2-negative HR-positive/HER-2-positive HR-negative/HER-2-positive HR-negative/HER-2-negative
  HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (>50 vs ≤50) 1.21 (0.85-1.73) 0.19 0.27 (0.11-0.70) 0.006 1.32 (0.47-3.73) 0.60 0.70 (0.44-1.13) 0.14
T stage (T3,4 vs T1,2) 2.00 (1.33-3.02) 0.001 2.74 (1.08-6.92) 0.03 1.40 (0.61-3.20) 0.42 1.22 (0.74-2.00) 0.44
No. of axillary nodes involved (3 < nodes vs ≤3 nodes) 1.18 (0.77-1.79) 0.45 0.93 (0.38-2.29) 0.88 2.42 (0.99-5.89) 0.054 1.52 (0.99-2.34) 0.057
HR status (positive vs negative) NA NA NA NA NA NA NA NA
HER-2 status (positive vs negative) NA NA NA NA NA NA NA NA
Adjuvant endocrine therapy (yes vs no) 1.01 (0.64-1.59) 0.98 0.72 (0.29-1.77) 0.47 NA NA NA NA
Adjuvant chemotherapy (yes vs no) 1.50 (1.03-2.19) 0.04 1.69 (0.70-4.08) 0.24 1.76 (0.68-4.53) 0.24 0.74 (0.40-1.36) 0.33
Relapse free interval (>2 yr vs ≤ 2 yr) 1.00 (0.67-1.50) 0.98 0.64 (0.30-1.37) 0.25 0.26 (0.11-0.61) 0.002 0.91 (0.55-1.52) 0.73
Site of first recurrence (visceral vs non visceral) 1.67 (1.17-2.39) 0.005 2.95 (1.36-6.41) 0.006 1.81 (0.77-4.27) 0.18 1.77 (1.12-2.79) 0.01
Brain metastatasis at diagnosis (yes vs no) 2.22 (0.68-7.27) 0.19 0.58 (0.06-5.33) 0.63 6.02 (1.87-19.3) 0.003 2.76 (0.97-7.83) 0.056
AIs and/or trastuzumab for recurrent disease (yes vs no) 0.37 (0.25-0.53) <0.001 0.55 (0.10-2.96) 0.49 0.61 (0.18-2.05) 0.42 NA NA
Time period (cohort B vs cohort A) 0.81 (0.50-1.30) 0.38 0.39 (0.19-0.79) 0.009 0.12 (0.05-0.29) <0.001 0.80 (0.50-1.29) 0.36
  1. Abbreviations: HR, hormone receptor; HER-2, human epidermal growth factor receptor 2; AI, aromtase inhibitors